-
Under the wave of new infrastructure, domestic medical equipment companies will take great strides!
Time of Update: 2022-12-04
(Image source: Pharma Network) Under the wave of new infrastructure, domestic medical equipment companies will take great strides!
(Image source: Pharma Network) In the secondary market, the activity of the medical device sector has also increased significantly, with the sector rising more than 18% since the low, standing out among the entire pharmaceutical and medical sectors.
-
1 survey of 12 institutions in 2003! Domestic soft mirror equipment head enterprises attract attention
Time of Update: 2022-12-04
js?cdnversion='+~(-new Date()/36e5)];Recently, because of a piece of equipment, the head enterprise of domestic soft mirror equipment, Aohua Endoscope, has attracted the attention of many investors.
js?cdnversion='+~(-new Date()/36e5)];Recently, because of a piece of equipment, the head enterprise of domestic soft mirror equipment, Aohua Endoscope, has attracted the attention of many investors.
-
The scale exceeds 600 billion, and innovative drug achievements are frequent Shanghai's pharmaceutical industry has shown strong resilience and vitality
Time of Update: 2022-12-04
It is reported that since the beginning of this year, Shanghai has started 32 new major projects with an investment of nearly 8 billion yuan, including the second phase of Bibo Bio's large-scale CDMO integrated platform, the construction project of Berger Medical Industrial Base, the intuitive Fosun headquarters and industrialization base, and the R&D capability and production quality improvement and transformation project of Hehuang Pharmaceutical.
-
Intelligent equipment is being more and more widely used in pharmaceutical production!
Time of Update: 2022-12-04
With the continuous improvement and application of digital technologies such as artificial intelligence, big data, and AI, more and more pharmaceutical companies in the pharmaceutical industry have begun to accelerate the development of new drugs and optimize production by using intelligent equipment and production lines.
-
The Science and Technology Biomedical ETF will be launched, focusing on innovative devices and innovative drugs
Time of Update: 2022-11-26
js?cdnversion='+~(-new Date()/36e5)];On November 9, five leading public offerings, including Huaxia Fund, Huaan Fund, Harvest Fund, Bosera Fund and ICBC Credit Suisse Fund, reported the Shanghai Securities Science and Technology Innovation Board Biomedical Transactional Open-ended Index Fund (hereinafter referred to as "Science and Technology Bio"), and the Science and Technology Innovation Biomedical ETF will be added to the Science and Technology Innovation Board sub-industry thematic ETF.
-
19 batches of drugs were unqualified, and Chinese medicine pieces were "named" again!
Time of Update: 2022-11-26
On November 15, the State Food and Drug Administration issued a notice on 19 batches of drugs that did not meet the regulations, and after inspection, 19 batches of drugs such as elderberry pills prod
-
CDE answers the common problem of chemical drugs - generic drugs
Time of Update: 2022-11-26
Question 1: Our company is now developing a single dose of oral solution, the prescription of the original development agent added preservatives, considering that the addition of preservatives is sti
-
Announcement of the State Food and Drug Administration on the management category of medical sodium hyaluronate products
Time of Update: 2022-11-26
In order to strengthen the supervision and management of medical sodium hyaluronate (sodium hyaluronate) products, further standardize the registration (filing) of relevant products, and ensure the safety and effectiveness of public pharmaceutical devices, in accordance with the relevant provisions of the Drug Administration Law and the Regulations on the Supervision and Administration of Medical Devices, the following announcement is made on matters related to the management of such products: 1.
-
The deputy general manager of this pharmaceutical company left! In the first three quarters, the company had 4 key R&D projects approved for clinical trials
Time of Update: 2022-11-26
According to the third quarterly report of 2022, the main revenue reached 944 million yuan, a year-on-year increase of 5.
According to the third quarterly report of 2022, the main revenue reached 944 million yuan, a year-on-year increase of 5.
-
Encourage the research and development of rare disease drugs to become a trend, and multinational pharmaceutical companies and local pharmaceutical companies actively deploy out
Time of Update: 2022-11-26
js?cdnversion='+~(-new Date()/36e5)];Data show that there are more than 20 million patients with various rare diseases in China, and more than 200,000 new patients are added every year.
-
Structure determines function, and the key physicochemical properties of adhesives help tablets form perfectly Webinar
Time of Update: 2022-11-26
18 / Friday / 14:00-15:00 Structure determines function, and the key physicochemical properties of adhesives help tablets form perfectly Dr. Yi Liu is Technical Director, Life Sciences, Asia Pacific, Ashland Excipients play an important role in the formulation molding process, and the function of excipients is determined by their structure.
-
The market prospect of new drugs for renal anemia is considerable, and domestic pharmaceutical companies are actively layout
Time of Update: 2022-11-26
In addition to tablets, Dongguang Pharmaceutical also has self-developed class 1 new drug HEC53856 capsules intended for the treatment of anemia associated with chronic kidney disease, including dialysis and non-dialysis patients.
-
Latest! EMA regulatory strategy adjustment for drug nitrosamine impurities_CPHI Pharma Online
Time of Update: 2022-11-26
Figure 1 Chemical structure of NKK and N-nitrosoduloxetine Image source: References It is worth noting that NKK is a simple nitrosamine impurity, which, like common NDMA, NDEA and other nitrosamine compounds, may be produced indiscriminately in the process of API or finished drug production.
-
Seven drug types of the market is rising, Panlong Pharmaceutical is facing raw material bottlenecks!
Time of Update: 2022-11-26
On the evening of October 27, Shaanxi Panlong Pharmaceutical Group Co. , Ltd. (Panlong Pharmaceutical, 002864. SZ) disclosed that the third quarter report of 2022 showed that in the first three quart
-
From January to September, the income of the basic medical insurance fund for urban and rural residents was 680.022 billion yuan
Time of Update: 2022-11-26
From January to September this year, the total expenditure of the national basic medical insurance fund (including maternity insurance) was 1.
From January to September this year, the total expenditure of the national basic medical insurance fund (including maternity insurance) was 1.
-
Pyruvate kinase deficiency (PKD) disease correction therapy! EU approves the first oral PK allosteric activator Pyrukynd (mitapivat)!
Time of Update: 2022-11-26
Nov. 12, 2022 /Biovalley BIOON/ -- Agios Pharmaceuticals has announced that the European Commission (EC) has approved Pyrukynd (mitapivat) for the treatment of adult patients with pyruvate kinase deficiency (PKD).
-
The State Food and Drug Administration announced the third batch of typical cases of special rectification of drug safety
Time of Update: 2022-11-26
Since the beginning of this year, in order to implement the decision-making and deployment of the Party Central Committee and the State Council on strengthening drug safety, the State Food and Drug A
-
Domestic pharmaceutical filling equipment to take the road of internationalization, but also need to overcome difficulties
Time of Update: 2022-11-26
Recently, some pharmaceutical people said on a forum that most of the current filling equipment is O-RABS (open restricted entry barrier system), many domestic filling equipment has filling interference operations, aseptic assembly, engineering design, unreasonable layout and other problems, and even open door operations are also many, if the future product is planned to be exported to Europe and the United States, it may be difficult to be accepted by European and American inspectors, because sterility management challenges are great.
-
The scale of China's CDMO market will move from tens of billions to hundreds of billions, and the head has increased its layout
Time of Update: 2022-11-26
5 billion yuan, and the funds raised will be used for the construction project (phase I project) of innovative drug CDMO (contract R&D and production organization) production base of Ribo (Taizhou) Pharmaceutical Co.
-
11 exclusive gynecological proprietary Chinese medicines are amazing! Yangtze River soars 127%
Time of Update: 2022-11-26
2022E China Urban Brick-and-mortar Pharmacy Gynecology Chinese Proprietary Medicine Brand TOP20Source: Competition pattern of drug terminals in China's urban physical pharmacies From the perspective of sales changes, Yangzijiang Pharmaceutical's peony granules and Guizhou Jianxing Pharmaceutical's Kangwu gel performed well, increasing by 127.
